On February 26, 2026, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with……
On February 02, 2026--Tenpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved YUVEZZI? (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.2%, previously known as BRIMOCHOL?……
Oct. 27, 2025 -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus?, the only oral GLP-2 medication available, for reducing the risk of major adverse cardiovascular events ……
Sep. 30, 2025 -- Novartis announced today that Rhapsido? (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain ……
On September 27, 2025, AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D2/D5 receptor partia……
Aug. 25, 2025 -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy? (semaglutide) injection 2.4 mg, treat adults with metabolic dysfunction-associated st……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
